Table 7.
Association analysis between enhancer and insulator HPSE gene SNPs and mobilization parameters after granulocyte colony-stimulating factor (G-CSF) administration to healthy donors.
| Parameters | rs4693608 | rs4693084 | rs4426765 | rs28649799 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | Median (Range) | p * | Genotype | Median (Range) | p * | Genotype | Median (Range) | p * | Genotype | Median (Range) | p | |
| CD34+ × 106 total yield |
AA (89) | 753.9 | 0.12 | GG (175) | 691.9 | 0.011 | AA (139) | 659.7 | 0.54 | AA (204) | 656.7 | 0.34 |
| (631.7–812.5) | (620.6–768.0) | (549.0–755.4) | (549.4–729.4) | |||||||||
| AG (125) | 634 | 0.12 | GT (78) | 561 | 0.26 | AC (90) | 675.6 | 0.67 | AG (41) | 682.5 | ||
| (545.9–711.3) | (479.1–651.4) | (521.3–758.9) | (495.8–988.7) | |||||||||
| GG (61) | 598.9 | 0.28 | TT (8) | 1022.3 | 0.0068 | CC (15) | 524.9 | 0.55 | ||||
| (493.1–727.1) | (598.9–1196.6) | (431.4–866.1) | ||||||||||
| CD34+ × 106/kg | AA (64) | 8.9 | 0.82 | GG (138) | 7.9 | 0.026 | AA (106) | 7.9 | 0.85 | AA (172) | 7.7 | 0.039 |
| (7.0–10.7) | (7.2–9.1) | (7.0–9.4) | (7.3–9.1) | |||||||||
| AG (105) | 7.7 | 0.86 | GT (66) | 8.2 | 0.53 | AC (82) | 8.4 | 0.52 | AG (32) | 10.9 | ||
| (7.4–9.1) | (7.5–9.5) | (7.3–10.7) | (7.5–13.1) | |||||||||
| GG (53) | 8.3 | 0.54 | TT (7) | 11.9 | 0.025 | CC (15) | 7.4 | 0.99 | ||||
| (6.9–10.0) | (7.6–23.5) | (5.5–11.9) | ||||||||||
| % CD34+ | AA (89) | 0.84 | 0.29 | GG (175) | 0.75 | 0.22 | AA (138) | 0.75 | 0.9 | AA (203) | 0.72 | 0.081 |
| (0.69–0.92) | (0.7–0.84) | (0.65–0.83) | (0.66–0.77) | |||||||||
| AG (126) | 0.72 | 0.08 | GT (78) | 0.68 | 0.38 | AC (91) | 0.72 | 0.9 | AG (42) | 0.84 | ||
| (0.62–0.77) | (0.57–0.76) | (0.66–0.77) | (0.69–1) | |||||||||
| GG (59) | 0.74 | 0.83 | TT (8) | 0.85 | 0.17 | CC (15) | 0.77 | 0.94 | ||||
| (0.64–0.84) | (0.49–1.29) | (0.59–0.85) | ||||||||||
| CD3+ × 108 total yield |
AA (88) | 270.7 | 0.99 | GG (173) | 276 | 0.73 | AA (138) | 273.7 | 0.054 | AA (202) | 275.2 | 0.41 |
| (255.4–300.0) | (262.8–300.2) | (258.3–297.8) | (264.6–300.0) | |||||||||
| AG (124) | 289.1 | 0.54 | GT (78) | 274.5 | 0.58 | AC (89) | 266.6 | 0.87 | AG (41) | 268.4 | ||
| (266.6–307.5) | (258.3–305.4) | (247.0–298.9) | (222.4–306.9) | |||||||||
| GG (61) | 268.9 | 0.67 | TT (8) | 266.2 | 0.77 | CC (15) | 336 | 0.044 | ||||
| (241.3–299.2) | (187.1–425.5) | (270.6–378.1) | ||||||||||
| CD3+ × 108/kg | AA (64) | 3.6 | 0.44 | GG (137) | 3.8 | 0.63 | AA (105) | 3.6 | 0.039 | AA (171) | 3.7 | 0.72 |
| (3.1–4.0) | (3.4–4.0) | (3.2–3.9) | (3.5–4.0) | |||||||||
| AG (104) | 3.9 | 0.69 | GT (66) | 3.8 | 0.83 | AC (82) | 3.9 | 0.37 | AG (32) | 3.8 | ||
| (3.5–4.3) | (3.2–4.3) | (3.3–4.2) | (3.0–4.7) | |||||||||
| GG (53) | 3.8 | 0.33 | TT (7) | 4 | 0.61 | CC (15) | 4.16 | 0.039 | ||||
| (3.4–4.2) | (2.2–5.5) | (3.5–5.9) | ||||||||||
| % CD3+ | AA (88) | 31.3 | 0.63 | GG (174) | 31.3 | 0.04 | AA (138) | 31.8 | 0.0042 | AA (202) | 31.4 | 0.97 |
| (28.9–33.9) | (29.6–32.4) | (30.3–33.6) | (29.8–32.7) | |||||||||
| AG (126) | 32.3 | 0.65 | GT (78) | 33.9 | 0.58 | AC (90) | 29.5 | 0.98 | AG (42) | 31.7 | ||
| (29.6–34.0) | (30.6–36.9) | (27.7–32.0) | (28.1–34.3) | |||||||||
| GG (59) | 31.9 | 0.76 | TT (8) | 26 | 0.03 | CC (15) | 39.9 | 0.0026 | ||||
| (29.8–35.9) | (10.8–29.8) | (32.4–43.9) | ||||||||||
| Neutrophils abs., 103/µL |
AA (90) | 13.9 | 0.66 | GG (175) | 14.3 | 0.032 | AA (140) | 14.9 | 0.25 | AA (205) | 14.4 | 0.41 |
| (11.2–17.0) | (12.5–17.0) | (12.5–19.2) | (12.5–17.0) | |||||||||
| AG (124) | 15.6 | 0.37 | GT (79) | 14.1 | 0.45 | AC (91) | 16.1 | 0.56 | AG (42) | 17.1 | ||
| (12.4–20.6) | (11.3–17.4) | (12.0–19.2) | (12.6–25.2) | |||||||||
| GG (61) | 13.6 | 0.91 | TT (8) | 24.8 | 0.042 | CC (15) | 13 | 0.25 | ||||
| (11.4–19.1) | (10.0–42.7) | (4.5–20.6) | ||||||||||
| Neutrophils, % | AA (90) | 43.4 | 0.77 | GG (176) | 41.5 | 0.12 | AA (140) | 43.1 | 0.017 | AA (206) | 40.6 | 0.54 |
| (37.5–49.5) | (35.7–47.3) | (37.3–47.6) | (33.2–44.8) | |||||||||
| AG (126) | 37 | 0.48 | GT (80) | 37.7 | 0.95 | AC (92) | 40.7 | 0.59 | AG (42) | 43.7 | ||
| (31.6–46.9) | (29.2–44.3) | (31.9–52.6) | (32.1–55.0) | |||||||||
| GG (61) | 38.7 | 0.82 | TT (8) | 56.8 | 0.12 | CC (15) | 28.2 | 0.015 | ||||
| (31.2–53.3) | (33–71.7) | (12.5–44.3) | ||||||||||
| Lymphocytes abs., 103/µL |
AA (90) | 9.8 | 0.75 | GG (175) | 9.9 | 0.12 | AA (140) | 9.9 | 0.017 | AA (205) | 10 | 0.94 |
| (7.4–12.3) | (8.8–12.2) | (8.4–12.2) | (9.4–12.2) | |||||||||
| AG (124) | 10 | 0.57 | GT (79) | 10.8 | 0.95 | AC (91) | 10 | 0.64 | AG (42) | 11.2 | ||
| (8.5–12.1) | (8.1–13.9) | (7.5–12.2) | (6.6–15.8) | |||||||||
| GG (60) | 10.3 | 0.99 | TT (8) | 3.7 | 0.1 | CC (15) | 21.5 | 0.013 | ||||
| (6.6–13.9) | (0.48–15.8) | (10.3–29.0) | ||||||||||
| Lymphocytes, % |
AA (90) | 31.8 | 0.77 | GG (176) | 26.5 | 0.049 | AA (140) | 23.5 | 0.026 | AA (206) | 26.3 | 0.91 |
| (19.7–38.8) | (19.7–34.4) | (18.8–32.1) | (19.7–34.3) | |||||||||
| AG (126) | 22.4 | 0.66 | GT (80) | 26.4 | 0.83 | AC (92) | 25.6 | 0.54 | AG (42) | 24.4 | ||
| (17.8–26.8) | (19.7–38.6) | (17.3–35.4) | (15.2–38.6) | |||||||||
| GG (61) | 30.4 | 0.47 | TT (8) | 9.5 | 0.049 | CC (15) | 55.9 | 0.023 | ||||
| (19.9–40.8) | (0.65–29.64) | (29.0–63.9) | ||||||||||
| Platelets, 103/µL | AA (89) | 297.8 | 0.32 | GG (175) | 323.7 | 0.24 | AA (138) | 323.9 | 0.068 | AA (204) | 324 | 0.22 |
| (258.6–326.5) | (303.9–339.9) | (300.2–349.8) | (304.7–345.8) | |||||||||
| AG (125) | 349 | 0.018 | GT (79) | 324.7 | 0.29 | AC (92) | 311.9 | 0.98 | AG (42) | 327.9 | ||
| (323.7–371.3) | (282.3–366.0) | (269.8–349.0) | (286.1–426.6) | |||||||||
| GG (61) | 324.7 | 0.72 | TT (8) | 369.5 | 0.29 | CC (15) | 375.6 | 0.059 | ||||
| (274.4–342.8) | (209.0–485.7) | (304.7–485.7) | ||||||||||
* The p value was indicated according to the following model: 1st p value—comparison between two homozygous genotypes; 2nd p value—correspondence of the first homozygous genotype to other genotypes; 3rd p value—comparison of the second homozygous genotype with other genotypes. Significant deviations (p ≤ 0.05) and the trend towards significance are marked in bold.